Last 40 quarters of trend data · Healthcare · Ophthalmology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 7.19 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 497.63 | 131.57 | 925.88 | 530.11 | 701.27 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -29.0% | -90.6% | -41.8% | -75.4% | -70.4% | |
| P/B Ratio | 0.00 | 0.01 | 0.19 | 110.67 | — | — | 6.37 | 132.10 | 192.28 | 78.31 | 168.30 | 126.51 | 101.12 | 99.58 | 66.37 | 152.87 | — | — | — | 234.20 | 139.96 |
| — | — | -97.0% | -16.2% | — | — | -96.2% | +4.4% | +90.2% | -21.4% | +153.6% | -17.2% | — | — | — | -34.7% | — | — | — | +21.4% | -29.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 57.1% | 15.5% | 43.5% | 23.6% | 70.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -18.8% | -76.7% | -37.2% | -19.2% | +19.1% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -3459.8% | -1277.1% | -2248.6% | -1401.0% | -850.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -307.0% | -34.2% | -159.4% | -8.2% | +27.0% | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 6922.1% | -1338.6% | -2400.9% | -2562.9% | -917.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +854.8% | -11.9% | -157.8% | -84.4% | +27.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -279.2% | -16.0% | -18.3% | 9.8% | — | -891.7% | -99.2% | -85.2% | -87.0% | -94.0% | -166.7% | -92.1% | -60.6% | -50.9% | -68.1% | -142.7% | — | — | -571.9% | -121.5% | -38.6% |
| — | +98.2% | +81.6% | +111.5% | — | -848.5% | +40.5% | +7.5% | -43.5% | -84.9% | -144.7% | +35.4% | — | — | +88.1% | -17.4% | — | — | -1872.5% | -302.4% | -62.3% | |
| ROA | -83.0% | -13.8% | -14.9% | 4.0% | -24.8% | -26.5% | -17.2% | -14.9% | -15.5% | -16.7% | -21.7% | -14.7% | -13.6% | -15.0% | -18.2% | -14.9% | 34.1% | -28.6% | -26.2% | -28.5% | -13.7% |
| — | +47.8% | +13.8% | +126.6% | -60.1% | -58.4% | +20.4% | -1.3% | -13.4% | -11.3% | -19.2% | +1.0% | -140.0% | +47.5% | +30.7% | +47.8% | +347.9% | -74.5% | -94.8% | -104.9% | -15.7% | |
| ROIC | — | -14.5% | -32.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -251.5% | -306.0% | -79.8% | -43.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -653.7% | -1394.8% | -423.6% | -193.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 5.67 | 2.62 | 5.40 | 2.68 | 5.49 | 4.84 | 3.22 | 1.92 | 1.42 | 2.26 | — | — | — | 4.77 | 1.74 |
| — | — | — | — | — | — | +3.2% | -46.0% | +68.0% | +39.8% | +287.1% | +113.8% | — | — | — | -52.6% | — | — | — | +372.8% | +82.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.81 | 6.88 | 7.91 | 3.81 | 0.75 | 2.10 | 1.99 | 3.11 | 2.15 | 3.07 | 4.22 | 6.33 | 5.62 | 6.65 | 6.95 | 3.35 | 2.10 | 2.54 | 3.00 | 3.32 | 5.48 |
| — | +227.4% | +297.6% | +22.2% | -65.3% | -31.5% | -52.8% | -50.8% | -61.8% | -53.9% | -39.3% | +89.3% | +167.1% | +162.0% | +131.7% | +0.7% | -61.6% | -61.4% | -66.5% | -56.9% | -39.8% | |
| Quick Ratio | 3.81 | 6.88 | 7.91 | 3.81 | 0.75 | 2.10 | 1.99 | 3.11 | 2.15 | 3.07 | 4.22 | 6.33 | 5.62 | 6.12 | 6.95 | 3.35 | 1.86 | 2.54 | 2.68 | 3.09 | 5.20 |
| — | +227.4% | +297.6% | +22.2% | -65.3% | -31.5% | -52.8% | -50.8% | -61.8% | -49.9% | -39.3% | +89.3% | +201.6% | +141.1% | +159.5% | +8.2% | -64.1% | -59.6% | -68.7% | -58.6% | -40.4% | |
| Interest Coverage | -7.24 | — | — | 5.87 | -6.85 | -9.32 | -7.20 | -4.87 | -5.06 | -5.57 | -7.11 | -4.88 | -7.20 | -6.54 | -6.83 | -5.80 | -10.04 | -12.15 | -15.16 | -12.53 | -12.58 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 40 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KALA stock.
KALA BIO, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking KALA BIO, Inc.'s business trajectory between earnings reports.